Sentien Biotechnologies, Inc., a regenerative medicine company developing cell based therapies for acute organ failure, is pleased to announce an initial round of financing by Boehringer [...]
Delivering on the promise of cell therapy
Sentien Biotechnologies, Inc. is a privately owned, late preclinical stage company developing novel approaches to cell therapy.
Our lead product, the Sentinel™, is designed to allow for controlled, sustained delivery of mesenchymal stem cell (MSC) secreted factors. This approach immobilizes the MSCs in an extracorporeal device, allowing for doses of therapeutic secreted factors that are unattainable by direct injection.